Key result
Fludrocortisone linked to ~15% LVEF improvement in a case of takotsubo cardiomyopathy and adrenal insufficiency.
Why the study?
Does fludrocortisone improve cardiac function in a patient with takotsubo cardiomyopathy secondary to adrenal insufficiency?
Case Report (n=1)
No
Does fludrocortisone improve cardiac function in a patient with takotsubo cardiomyopathy secondary to adrenal insufficiency?
Secondary adrenal insufficiency is a rare cause of takotsubo cardiomyopathy that can be effectively managed with fludrocortisone to improve cardiac function and hemodynamic stability.
May warrant fludrocortisone in adrenal insufficiency-related takotsubo; hypothesis-generating pending prospective validation.
We present a case of a middle-aged woman with a prolonged history of diarrhea, vomiting, and abdominal pain. Upon admission to the ICU, she exhibited hypotension and hypoglycemia. Based on presenting gastrointestinal complaints, she was initially treated for acute gastroenteritis; however, continuous refractory hypotension led to an echocardiographic assessment. A left ventricular ejection fraction (LVEF) of 30-35% with apical akinesis and distinct apical ballooning was visualized on a transthoracic echocardiogram, suggestive of takotsubo cardiomyopathy. An increasing inotropic demand raised concerns regarding alternative etiologies. Further evaluation revealed decreased adrenocorticotropic hormone and cortisol levels, leading to a diagnosis of secondary adrenal insufficiency. Treatment with fludrocortisone significantly improved her adrenal insufficiency and her cardiomyopathy. This case highlights secondary adrenal insufficiency as a rare but potential cause of takotsubo cardiomyopathy in Pakistan, with the use of fludrocortisone as a treatment option in a carefully selected patient.
No takes yet. Share an insight, caveat, or question.
Khalid et al. (2026) conducted a case report in Middle-aged woman (44 years) with secondary adrenal insufficiency and takotsubo cardiomyopathy due to chronic topical steroid use (n=1). Fludrocortisone was evaluated on Improvement in left ventricular ejection fraction (LVEF) (LVEF improved from 30-35% to 45-50%). Fludrocortisone improved left ventricular ejection fraction from 30-35% to 45-50% in a middle-aged woman with secondary adrenal insufficiency and takotsubo cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: